SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
ReCyte Therapeutics and OncoCyte Corporation Release: BioTime Licenses Technology for Key Regulatory Gene Underlying Cancer and Stem Cell Reprogramming from The Wistar Institute